

AGENDA

Stem cell transplantation (WP14)

Tuesday, February 2, 2010

17.30 – 19.30 h

Congress Center Rosengarten Mannheim

Gustav Mahler III

Niederwieser, Lowenberg, Sierra, Dombré, Cornelissen, Verdonck, Gratwohl, Rocha	Randomized study in patients with AML over the age of 60 a studying the role of SCT with reduced intensity conditioning. Start study
Gahrton/Garderet	MMVAR Study to treat relapse in myeloma after autologous SCT (40 patients)
Brune	Related allo-SCT after Reduced Intensity Conditioning versus Best Standard of Care in elderly patients with AML in CR1 (Brune)
Schleuning**, Guilhot	AlloSCT after TKI in CML
Niederwieser, Gahrton, Gratwohl,	Role of unrelated allogeneic SCT after autologous SCT in comparison to second autologous SCT in multiple myeloma (NMMA 2005, start study)
Niederwieser, Bleileven, deWitte,	Study investigating the role of Kevivance for treating Mucositis after autologous SCT (350 patients)
Gratwohl, Niederwieser	Comprehensive survey outside Europe (publication)
Gratwohl	Integration of risk factor profiling into risk adapted therapy pilot AML HOVON/SAKK <60 years
Heim**, Gratwohl	Autologous SCT for CML (30 patients reported to the EBMT). Evaluation
Heim**, Gratwohl	Outcome of patients with low risk Gratwohl score CML
Ruutu	Guidelines for secondary allotransplantation after relapse (retrospective analysis)
Olavarria, Schleuning**	prospective Feasibility study phase II Dasatinib for relapse in CML after allo
Jedrzejczak	T-PLL after autologous and allogeneic SCT (44 patients)
Jedrzejczak	Prospective registration audit for T-PLL
Gahrton, Niederwieser	Phase II study comparing sibling donor RIC allotransplantation to autologous transplantation (NMAM 2000) manuscript ready
Kröger deWitte	Allogeneic reduced intensity conditioning transplantation versus conventional conditioning in MDS (RICMAC) Study start
Niederwieser, Gratwohl, Apperley	AML Guidelines manuscript ready
Niederwieser, Gratwohl, Apperley	CML Guidelines manuscript ready